Fig. 1.
MAdCAM-1 is present in livers of PSC-IBD patients and not increased in colonic tissue of PSC-IBD patients compared to IBD patients.
A: Immunohistochemistry of MAdCAM-1 on frozen sections, 10x magnification. Representative pictures of long-term PSC-IBD (PSC-IBDLT) liver (left) and control liver (middle). Ileum tissue was used as positive control (right). B: H-score of immunohistochemical MAdCAM-1 staining in control liver (n = 6) and PSC-IBDLT liver (n = 7). H-score was calculated as [3 x percentage of strongly staining cells] + [2 x percentage of moderately staining cells] + [percentage of weakly staining cells]. C: Relative mRNA expression of MAdCAM-1 in livers of control patients (n = 10) and PSC-IBDLT patients (n = 8). D: Spearman’s Rho correlation between MAdCAM-1 H-score and VAP-1 intensity in livers of patients with PSC-IBDLT (n = 6). E: Representative picture of immunohistochemistry of MAdCAM-1 on FFPE colon sections, 10x magnification. Expression of MAdCAM-1 on endothelium of a patient with PSC-IBD (arrows). F: Difference in MAdCAM-1 staining between endoscopically inflamed colonic biopsies (n = 4) and non-inflamed biopsies (n = 22) of PSC-IBD and IBD patients (left panel). H-score of immunohistochemical MAdCAM-1 staining on endothelium in colon of IBD patients (n = 10) and PSC-IBD patients (n = 16) (right panel).Data presented as median. Statistical testing was performed using the Mann-Whitney U test for comparisons between groups. A p-value <0.05 was considered statistically significant (∗p < 0.05).